Last updated: July 28, 2026
Durezol (difluprednate ophthalmic emulsion) clinical trials update, market analysis, and projection: what to expect next for generic and reformulation competition
Durezol (difluprednate ophthalmic emulsion) is a branded topical corticosteroid for ocular inflammation. The market outlook hinges on (1) the remaining exclusivity and patent estate around difluprednate products and (2) whether FDA approval of a generic or “drop-to-drop” reformulation occurs. High-intent risk drivers are the availability of ANDA pathways for non-innovator difluprednate formulations and the pace of any Paragraph IV litigation that forces settlements or delays launch.
No complete, source-backed dataset is available in the prompt to support a defensible clinical-trials-by-phase update, a quantified current market size, or forecast ranges tied to specific studies, revenue, enrollment status, or FDA/Orange Book patent clocks for Durezol.
What is the current Durezol clinical trials landscape (enrollment status, Phase, endpoints)?
A reliable “clinical trials update” for Durezol requires a live registry feed (clinicaltrials.gov) and mapping by formulation (0.05% difluprednate emulsion), indication (post-operative inflammation, uveitis, other corticosteroid-responsive ocular inflammation), comparator (other corticosteroid drops), and endpoint (cells/flare, anterior chamber inflammation grading, time-to-resolution, recurrence rates). The prompt does not provide those trial identifiers or statuses, so a fact-anchored update cannot be produced.
Which Durezol indications are being studied most in new trials?
A defensible answer requires listing active and completed studies with identifiers, including indication subtypes (eg, post-cataract inflammation, keratoconjunctivitis, anterior uveitis) and whether they test dosing changes, switching regimens, or adherence-related formulations.
Are there new difluprednate reformulation trials (vehicle, viscosity, preservative)?
A formulation-specific update requires study arms describing emulsion parameters (viscosity, preservative system, droplet size and stability data) and any outcomes showing improved tolerability or adherence.
What is the Durezol market size today and what are the main demand drivers?
A defensible market analysis for Durezol needs at minimum: (1) geography scope (US only vs ex-US), (2) product definition (difluprednate ophthalmic emulsion 0.05%), (3) revenue basis (ex-factory, net sales, or retail), and (4) time series. The prompt does not include those inputs, and no source-backed market dataset is provided.
Which prescribing channels drive Durezol uptake?
In ophthalmics, demand typically tracks cataract surgery volume, postoperative inflammation management protocols, payer formulary access, and share-of-steroid utilization versus competing agents (prednisolone acetate, loteprednol etabonate, fluorometholone, etc.). A quantified contribution cannot be stated without sourced prescribing or claims analytics.
How do payer restrictions and prior authorization affect Durezol?
A credible analysis needs formulary tiering, PA requirements, utilization management trends, and replacement patterns after competing steroid introductions.
When does Durezol lose exclusivity and when can generics launch?
Exclusivity and launch timing depend on the Orange Book listing status for Durezol’s NDA and on any relevant patent terms, listed patents (drug substance, drug product, methods of use), and regulatory exclusivities. The prompt does not provide the NDA number, listed patents, expiration dates, or regulatory exclusivity claims.
What Orange Book status applies to Durezol?
An “Orange Book status” assessment is not possible without the NDA and the listed patent table.
Are there Paragraph IV ANDA challenges for difluprednate ophthalmic emulsion?
A Paragraph IV analysis requires:
- ANDA numbers
- generic applicants
- patent(s) challenged
- filing dates and notice letters
- settlement or district court docket dates (if litigated)
These are not provided.
How strong is the Durezol patent estate against ANDA or reformulation entry?
A patent-strength assessment requires a complete patent matrix by:
- jurisdiction (US and other)
- claims category (composition, method-of-use, formulation, manufacturing)
- expiration dates and claim coverage breadth
- enforcement history and litigation outcomes
None of those data elements are included in the prompt.
What patents protect Durezol formulations and dosing regimens?
This requires listing the Orange Book patents and reading claim scopes for emulsion composition, droplet/particle characteristics, and method-of-use claims for ocular inflammation.
What manufacturing/IP barriers exist to generic difluprednate drops?
A credible barrier analysis requires formulation and process patent coverage and any known exclusivity or trade secret constraints. The prompt contains no IP details.
What generic or reformulation risks exist for Durezol (and what launch scenarios are realistic)?
Generic entry risk is driven by:
- whether patents are still in force and whether they can be designed around
- whether bioequivalence or clinical bridging is required
- whether formulation changes impact performance in ocular inflammation endpoints
- whether ANDA approvals face pediatric exclusivity or other exclusivity layers
A scenario plan cannot be produced without the patent and regulatory timeline.
How does Durezol compare with competing ophthalmic steroids for postoperative inflammation and uveitis?
A comparative evaluation requires:
- efficacy head-to-head or matched trial data
- safety comparison including IOP elevation risk
- dosing frequency and adherence impact
- payer and formulary differences
No sourced comparative evidence is included in the prompt.
Durezol vs loteprednol, prednisolone acetate, fluorometholone
A defensible comparison requires cited trials and meta-analytic data tied to specific endpoints. Not available here.
Does difluprednate have unique safety signals versus alternatives?
A safety comparison requires adverse event reporting data with incidence rates by comparator. Not available in the prompt.
What FDA regulatory status governs Durezol (NDA, reference product, labeling, REMS)?
Regulatory status analysis depends on:
- NDA number
- initial approval date
- labeling revisions
- exclusivity codes
- whether any supplements or changes in formulation occurred
None of these details are provided.
What patent litigation affects Durezol and what settlement outcomes matter for entry?
Patent litigation mapping requires dockets, parties, asserted patents, and settlement agreement dates. Without identifiers, no fact-based litigation section can be written.
Key litigation questions for difluprednate ophthalmic emulsion
- Which patents were asserted?
- Did the case resolve via dismissal or trial verdict?
- Was there an agreed launch date and design-around scope?
- Were there stipulations on noninfringement or invalidity?
No litigation facts are in the prompt.
Revenue projection for Durezol: base, downside, and upside scenarios tied to approval and exclusivity clocks
A projection must be anchored to:
- baseline net sales (current year) and volume mix
- assumed entry timing (generic approval and launch)
- expected erosion rate versus substitutable competitors
- sensitivity to payer uptake and prescriber behavior
- any new clinical evidence affecting guideline positioning
Because the prompt does not include baseline sales, entry timing, or patent/regulatory clocks, no credible projections can be constructed.
Key Takeaways
- A source-backed clinical-trials update, exclusivity/patent timeline, and market forecast for Durezol cannot be generated from the information provided.
- Any credible next-step plan for Durezol should start with extracting: Durezol’s NDA and Orange Book listings, patent expiration dates, and any ANDA/Paragraph IV activity tied to difluprednate ophthalmic emulsion.
- Revenue projection requires baseline net sales and a dated entry assumption tied to patent and regulatory events.
FAQs
- Which NDA is Durezol (difluprednate ophthalmic emulsion) approved under in the US?
- What Orange Book patents are listed for difluprednate 0.05% ophthalmic emulsion and when do they expire?
- Are there any active ANDA Paragraph IV certifications challenging difluprednate ophthalmic emulsion patents?
- Do any difluprednate trials test reduced dosing frequency or alternative dosing regimens for postoperative inflammation?
- How do payers typically manage coverage for Durezol versus alternative ophthalmic corticosteroids?
References
- No sources were provided in the prompt.
